# PharmaCCX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharmaccx

- Industry: Healthcare IT
- Headquarters: Boston, US
- Website: www.pharmaccx.com
- Total disclosed funding: $3M
- Latest round: Series A (May 12, 2020)
- Investors on record: 4

## About

PharmaCCX, Inc. specializes in innovative software solutions that enhance contract management and market access for pharmaceutical companies and payers, streamlining complex processes in the healthcare ecosystem.Founded in 2017 and headquartered in Boston, US, PharmaCCX, Inc. provides software solutions that facilitate effective contract management for the pharmaceutical sector. Nathan Sigworth serves as both the Founder and CEO, bringing a strong background in business development. The company has raised a total of USD 3.00 mn, primarily through its Seed funding round led by Accel, which took place on May 12, 2020, with participation from Alumni Ventures Group and Atlantic Labs. The company has completed two funding deals to date.PharmaCCX offers a suite of software solutions aimed at simplifying contract management and improving market access for pharmaceutical companies and payers. Their key products include CCX Planning, CCX Workflows, CCX Catalogue, and CCX Digital Negotiation, designed to reduce administrative burdens and enhance collaboration among stakeholders. These tools enable users to model and analyze contract scenarios while streamlining negotiations, particularly catering to clients in North America and Europe. By optimizing workflows for access agreements, PharmaCCX significantly reduces the time required to finalize deals.PharmaCCX operates on a subscription-based revenue model that targets pharmaceutical companies and payers. Services like CCX Digital Negotiation and CCX Workflows are offered as subscription plans, tailored to client needs, which helps them manage contract processes efficiently. This model supports scalable solutions adaptable to the evolving demands of the pharmaceutical industry, with additional revenue potential arising from partnerships with payers.PharmaCCX is actively developing new products to enhance its software suite further and plans to enter additional markets in the near future. Alongside ongoing expansions in capabilities, the company is exploring opportunities for market entry in Asia and South America by the end of 2021. The recent Seed funding of USD 3.00 mn will support these initiatives, allowing for the acceleration of product development and market outreach efforts.

## Funding rounds

- Series A, May 12, 2020 — Accel, Atlantic Labs, FJ Labs
- Seed, Nov 20, 2018, $3M — Accel, Alumni Ventures Group, Atlantic Labs

## Investors

- Accel (https://capitalatlas.ai/funds/accel) — Seed, Series A
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Seed
- Atlantic Labs (https://capitalatlas.ai/funds/atlantic-labs) — Seed, Series A
- FJ Labs (https://capitalatlas.ai/funds/fj-labs) — Series A